Wealth Enhancement Advisory Services
IRWD icon

Wealth Enhancement Advisory Services’s Ironwood Pharmaceuticals IRWD Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$913K Sell
219,445
-7,243
-3% -$27.9K ﹤0.01% 2139
2026
Q1 		$741K Buy
226,688
+71,165
+46% +$292K ﹤0.01% 2025
2025
Q4 		$665K Buy
155,523
+1,135
+0.7% +$2.95K ﹤0.01% 2262
2025
Q3 		$235K Buy
154,388
+28,928
+23% +$29.9K ﹤0.01% 2989
2025
Q2 		$96.1K Buy
125,460
+101,574
+425% +$79.7K ﹤0.01% 3144
2025
Q1 		$35.1K Buy
23,886
+10,651
+80% +$25.4K ﹤0.01% 2874
2024
Q4 		$58.6K Buy
+13,235
New +$53.7K ﹤0.01% 2854
2024
Q3 		– Sell
-13,608
Closed -$88.7K – 2863
2024
Q2 		$88.7K Buy
+13,608
New +$96.3K ﹤0.01% 2417

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wealth Enhancement Advisory Services's IRWD Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Ironwood Pharmaceuticals (IRWD) stake by 3.2% in Q2 2026, selling an estimated $27.9K and leaving 219,445 shares worth $913K. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Wealth Enhancement Advisory Services first reported a position in IRWD in Q2 2024 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Wealth Enhancement Advisory Services held 219,445 shares of Ironwood Pharmaceuticals worth $913K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 7,243 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2139 holding.
  • Wealth Enhancement Advisory Services first reported a position in Ironwood Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.